Existing drug shows promise in treating deadly dementia that strikes early Drugs that boost the function of a specific type of neurotransmitter receptor may benefit patients with frontotemporal dementia — the second most common type of dementia.
UAB research published in the Journal of Neuroscience offers hope that cycloserine, a drug already approved for use by the FDA, may be an effective therapeutic agent.
FTD is a devastating disease that usually strikes people in their mid to late 50s, who often die within 10 years because there is no effective treatment.
Clinical research program to combat chronic fatigue, pain
A life in lasers In the high-powered world of laser research, UAB physicist Sergey Mirov, Ph.D., is a leading light.
Mirov, who began his career in Russia, has spent more than two decades at UAB, improving all aspects of laser technology. That work has generated more than 20 patents and has many potential scientific and medical applications, including a laser scalpel and an “optical nose” to detect organic materials.
Now, Mirov has been named as a fellow in the National Academy of Inventors, becoming UAB’s fifth recipient of this prestigious distinction.